Table 2 Demographics and clinical parameters at baseline according to osteoprotegerin (OPG) quintiles in the GCKD cohort (n = 4 246)

From: Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort

 

Osteoprotegerin/(pmol·L−1)

Characteristics

Q1 (≤4.8)

Q2 (>4.8–≤5.9)

Q3 (>5.9–≤7.1)

Q4 (>7.1–≤8.7)

Q5 (>8.7)

n/%

850 (20.0)

849 (20.0)

849 (20.0)

850 (20.0)

848 (20.0)

Age/years

52.2 ± 13.4

56.6 ± 12.1

61.9 ± 9.9

64.5 ± 8.7

66.2 ± 8.4

Male, n/%

568 (13.4)

535 (12.6)

534 (12.6)

494 (11.6)

478 (11.3)

Systolic BP/mmHg

134.8 ± 17.6

137.6 ± 18.8

138.8 ± 19.8

143.2 ± 22.0

142.7 ± 22.1

Diastolic BP/mmHg

80.7 ± 11.4

80.4 ± 11.6

79.3 ± 11.9

78.7 ± 11.8

76.4 ± 12.3

BMI/(kg·m–2)

29.2 ± 5.4

29.7 ± 6.0

30.1 ± 6.2

30.7 ± 6.3

29.7 ± 5.9

Diabetes, n/%

183 (4.3)

223 (5.3)

289 (6.8)

389 (9.2)

438 (10.3)

Previous CVD, n/%

150 (3.5)

163 (3.8)

223 (5.3)

278 (6.5)

309 (7.3)

Smoking

 Never, n/%

340 (8.0)

334 (7.9)

335 (7.9)

341 (8.1)

349 (8.2)

 Former, n/%

344 (8.1)

348 (8.2)

385 (9.1)

387 (9.1)

371 (8.8)

 Current, n/%

164 (3.9)

165 (3.9)

127 (3.0)

120 (2.8)

124 (2.9)

 Unknown, n/%

2 (0.0)

2 (0.0)

2 (0.0)

2 (0.0)

4 (0.1)

eGFR/(mL·min–1 per 1.73 m2)

53.8 ± 20.3

51.5 ± 17.8

47.4 ± 16.3

46.0 ± 15.7

42.6 ± 14.5

UACR/(mg·g–1)

72.4 (11.8–498.0)

54.3 (9.4–420.5)

31.3 (8.3–308.5)

46.8 (9.7–352.5)

62.6 (10.8–351.5)

hsCRP/(mg·L−1)

1.8 (0.8–4.0)

2.0 (0.9–4.7)

2.4 (1.1–5.4)

2.5 (1.2–5.2)

3.0 (1.4–6.7)

Serum albumin/(mg·L−1)

39.2 (36.7–41.3)

38.9 (36.6–41.0)

39.0 (36.5–41.0)

38.3 (36.1–40.6)

37.8 (35.3–40.2)

LDL cholesterol/(mg·dL−1)

115.1 (90.9–144.7)

115.8 (92.8–147.1)

114.3 (89.4–141.2)

112.0 (87.0–141.3)

106.6 (81.5–137.5)

HDL cholesterol/(mg·dL−1)

46.6 (37.9–59.4)

48.2 (39.1–59.7)

47.3 (39.2–59.8)

49.0 (39.7–60.8)

49.2 (39.3–63.4)

RASi, n/%

732 (17.2)

715 (16.8)

731 (17.2)

721 (17.0)

701 (16.5)

Statins, n/%

353 (8.4)

383 (9.1)

423 (10.0)

461 (10.9)

439 (10.4)

Beta blocker, n/%

391 (9.3)

415 (9.8)

506 (12.0)

532 (12.8)

516 (12.2)

Thrombocyte aggregation inhibitors, n/%

194 (4.6)

260 (6.2)

309 (7.3)

368 (8.7)

384 (9.1)

Aldosterone antagonists, n/%

58 (1.4)

54 (1.3)

67 (1.6)

80 (1.9)

84 (2.0)

Vitamin D therapy, n/%

260 (6.2)

239 (5.7)

255 (6.1)

272 (6.5)

294 (6.9)

  1. Continuous variables are presented as the mean and standard deviation or median and interquartile range. Categorical variables are presented as absolute numbers and as percentages
  2. OPG osteoprotegerin, eGFR estimated glomerular filtration rate, UACR urine albumin creatinine ratio, hsCRP high-sensitivity C-reactive protein, LDL low-density lipoprotein, HDL high-density lipoprotein, BP blood pressure, CVD cardiovascular disease, BMI body mass index, RASi renin-angiotensin system inhibitor
Back to article page